Pregled bibliografske jedinice broj: 1117995
Safety and Efficacy Profile of Live, Intermediate Plus Vaccine Against Infectious Bursal Disease Based on Strain G6
Safety and Efficacy Profile of Live, Intermediate Plus Vaccine Against Infectious Bursal Disease Based on Strain G6 // Viral Immunology, 34 (2021), 2; 117-127 doi:10.1089/vim.2020.0204 (međunarodna recenzija, članak, ostalo)
CROSBI ID: 1117995 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Safety and Efficacy Profile of Live,
Intermediate Plus Vaccine Against Infectious
Bursal Disease Based on Strain G6
Autori
Huić Babić, Katarina ; Ljuma Skupnjak, Lana ; Zorman Rojs, Olga ; Halas, Máté ; Vrdoljak, Anto
Izvornik
Viral Immunology (0882-8245) 34
(2021), 2;
117-127
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, ostalo
Ključne riječi
infectious bursal disease virus, gumboro disease, intermediate plus vaccine, vaccination, G6, vaccine efficacy, European pharmacopoeia, breakthrough titer
Sažetak
Infectious bursal disease (IBD) is an acute, highly contagious, immunosuppressive disease of young chickens that causes considerable economic loss in the poultry industry worldwide. Vaccination with live attenuated vaccines is still the most important method used for the control and prevention of IBD in chickens. Here we present the results of in vitro characterization, as well as efficacy and safety testing of a live, intermediate plus vaccine against IBD based on strain G6. Strain characterization confirmed that G6 strain is an intermediate plus strain, showing a high degree of homology with the existing vaccine strains of the same virulence. Safety studies showed that chickens can be vaccinated from 10 days of age. Onset and duration of immunity in specific pathogen free and maternally derived antibodies (MDA) chickens was proven to be 14 and 35 days after vaccination, respectively. When immunizing MDA- positive chickens, vaccine is capable of breakthrough at a titer of £500 ELISA units. The field trial conducted on commercial broilers showed a 95% protection against vvIBDV challenge. Stability of the freeze-dried vaccine after reconstitution was confirmed over a period of 3 h. Overall, IBD G6 vaccine has shown good safety and efficacy profile in accordance with European Pharmacopoeia requirements.
Izvorni jezik
Engleski
Znanstvena područja
Veterinarska medicina, Biotehnologija, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)
POVEZANOST RADA
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE